Bioventus Inc. (BVS) stock
BVSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 26, 2026Last filing: 10-Q on Nov 2, 2026Score 14/3033% below fair value
$10.66−0.20 (-1.84%)
Close on Nov 13, 2026Market cap $896.42MP/E 13.3Yield –
Bioventus price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Bioventus's price to sales ratio was 1.3× on Nov 11, 2026, against 0.9× a year earlier. Over the last 5 years it ranged from 0.1× to 1.6×, with a median of 0.8×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 1.3× | +0.4 |
| 2025 | Dec 31, 2025 | 0.9× | −0.3 |
| 2024 | Dec 31, 2024 | 1.2× | +0.6 |
| 2023 | Dec 29, 2023 | 0.7× | +0.4 |
| 2022 | Dec 30, 2022 | 0.3× | – |
See a number that looks wrong?